Clinical Trials

Are you between 40 and 85 with worsening idiopathic pulmonary fibrosis? This study aims to test a new combination treatment for acute exacerbations, a life-threatening complication of idiopathic pulmonary fibrosis (IPF) that has no approved treatment. The treatment is meant to help stop part of the immune system from further injuring the lung tissue. To participate in this study, you must be between 40 and 85 years old and have worsening IPF. This study is located in Birmingham, Alabama; Boston, Massachusetts; Philadelphia, Pennsylvania; and Pittsburgh, Pennsylvania.

Are you an adult who has overweight or obesity and would be interested in a weight-loss study? This study is testing whether a medicine called phentermine is safe and effective for treating obesity over a long period. This study has multiple locations in the United States.

Are you between 65 and 85 years old and are a patient at Stanford? This study will evaluate the effect of an electronic health record (EHR) screening tool on rates of new noninvasive testing, diagnosis, and treatment of peripheral artery disease (PAD) over a 6-month period. The EHR-based screening tool will generate a group of patients at the highest risk of having undiagnosed PAD to participate in the study. To participate in this study, you must be between 65 and 85 years old, have at least 1 year of data with the Stanford EHR, and have no prior diagnosis of PAD. This study takes place in Palo Alto, California.